Will Big Pharma get the bug for microbiome therapies?

The microbiome therapeutics field is dominated by many innovative small and medium-sized enterprises (SMEs), all focused on driving the development of a single or a small pipeline of biotherapeutics. This has resulted in an impressive range of innovative products in development, often targeting conditions which conventional “small molecule” drug discovery projects have failed to adequately address.